In Graves' disease, which immunoglobulin subclass is responsible for TSH receptor stimulation and the induction of exophthalmos?

Explanation

## Immunoglobulin Subclass in Graves' Disease **Key Point:** IgG is the pathogenic antibody in Graves' disease. Specifically, IgG1 and IgG3 subclasses bind to TSH receptors on thyroid follicular cells and orbital fibroblasts, causing both thyroid hormone overproduction and ophthalmopathy. ### Pathogenic Mechanism of TSH Receptor Antibodies (TRAb) 1. **IgG antibodies** bind to TSH receptor (TSHR) on thyroid cells 2. Antibody-receptor binding mimics TSH signaling → cAMP ↑ → thyroid hormone synthesis ↑ 3. **IgG also crosses into orbital tissue** → binds TSHR on orbital fibroblasts and preadipocytes 4. Fibroblast activation → cytokine release → inflammation, adipogenesis, edema → exophthalmos 5. IgG can also activate complement → further tissue damage ### Why IgG and Not Other Immunoglobulins? | Immunoglobulin | Why Not Pathogenic in Graves' | | | --- | --- | --- | | **IgM** | Pentameric; does not cross blood–brain barrier or orbital tissue easily; early response, not sustained | | | **IgG** | **✓ Monomeric; crosses tissue barriers; sustained response; activates Fc receptors and complement** | | | **IgA** | Primarily mucosal immunity; not involved in systemic autoimmunity | | | **IgE** | Involved in allergic/parasitic responses; not relevant to Graves' pathogenesis | | **High-Yield:** IgG is the **only immunoglobulin that crosses the placenta** — this is why neonates born to mothers with Graves' disease can develop transient neonatal Graves' disease (TSH receptor antibodies from maternal IgG). ### Clinical Correlation: Neonatal Graves' Disease - Maternal IgG TRAb crosses placenta → fetal thyroid stimulation - Neonatal hyperthyroidism appears within 24–72 hours of birth - Self-limited; resolves as maternal IgG is catabolized (half-life ~2 weeks) - Risk: ~1–5% of infants born to mothers with Graves' disease **Clinical Pearl:** Measurement of **TSH receptor antibody (TRAb) titers** in the third trimester of pregnancy predicts risk of neonatal Graves' disease. High titers warrant close fetal and neonatal monitoring.